PD-L1 Antibody – 149Sm

Catalog: 714901                                          Clone: E1L3N                                            Isotype: Rabbit IgG
Reactivity: Human*
Storage: PD-L1 antibody is supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C
IHC: PD-L1 antibody staining of FFPE human placenta
MIBI: PD-L1 antibody staining (cyan) of FFPE human placenta, counterstained with dsDNA (magenta)
IHC: PD-L1 antibody staining of FFPE human tonsil
MIBI: PD-L1 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)
Background: Programmed cell death 1 ligand 1 (PD-L1, CD274) binds to PD-1 and inhibits T cell activation. APCs, activated T cells, and tissues including placenta, heart, and lung can express PD-L1. PD-L1 is expressed in cancer as a means for cancerous cells to inhibit immune responses. PD-L1 has been detected for several tumor types including melanoma, lung, ovary, colon, breast, and renal cell carcinomas. PD-L1 expression in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Inhibition of the PD-1-PD-L1 axis has been an active area of clinical research with several approved drugs for multiple indications.

Validation: Each lot of conjugated PD-L1antibody is quality control tested by MIBIscope™ analysis of stained tissue microarray using the appropriate positive and negative tissue field of views and are pathologist verified.

Recommended Usage: 1 uL of PD-L1 antibody per 100 uL staining volume using the MIBI™ Staining Protocol.
For optimal results, antibody should be titrated for each desired application.  Suggested starting range is 1:100.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.


  • Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015; 3(4): 326-332.
  • Bindels, S. et al. Regulation of PD-L1 by SIP1 in human epithelial breast tumor cells. Oncogene. 2006; 25:4975–4985.

* Conjugate tested on human tissue.

Contact Us

Let us know how we can help you.

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.